Breaking Uranium Stock News - Pegasus Resources (TSXV: $PEGA) (OTC PINK: $SLTFF) Reports Historical Utah Data; @pegasusresinc

Breaking Uranium Stock News - Pegasus Resources (TSXV: $PEGA) (OTC PINK: $SLTFF) Reports Historical Utah Data; @pegasusresinc

Vancouver, Canada - June 4, 2024 (Investorideas.com Newswire) Pegasus Resources Inc. (TSX-V:PEGA) (OTCPK:SLTFF) (Frankfurt:0QS0) (the "Company" or "Pegasus") has retained Dahrouge Geological Consulting USA Ltd. ("Dahrouge") to complete a preliminary geological model based on detailed geological mapping and sampling completed on the Company's Energy Sands project (the "Property") located in Utah in Q1 2024 (see press releases dated Jan. 16, Jan. 30 and Mar 25, 2024). The outcome of the ground program provided a detailed geological map inclusive of lithologies, geological structure, mineralization style and controls, along with confirmation of paleochannel structures controlling the uranium and vanadium mineralization present on the Property. Dahrouge used this collected data in conjunction with the 2015 Utah Geological Survey regional map and stratigraphic column (Doelling et al., 2015) as a reference framework to build a preliminary geological model to support Pegasus' permitting efforts for the planned upcoming drill program in 2024.

 

This news is paid advertisement/ news disseminated on behalf of/issued on behalf of Pegasus Resources Inc.

 

Read this news featuring PEGA in full at https://www.investorideas.com/news/2024/06041PEGA-Historical-Utah-Data.asp

 

The generation of the geological model was a crucial step in understanding the Property's geology and mineralization. This preliminary geological model was then used as a basis to define drill targets for the planned drill program and support and submittal of a Notice of Intent to the Bureau of Land Management ("BLM") Price, Utah Field Office. As part of the Notice of Intent submittal, all surface disturbances (access roads, drill pads, etc.) must be defined and presented to the BLM.

 

During the generation of the geological model and a Notice of Intent filing, Pegasus was provided with historical drilling data completed on the Property in 1975. This data was inclusive of a drillhole location map, geological logs, downhole geophysical surveys (presented in counts per minute "CPM") and interval analytical values for uranium and vanadium from eleven (11) drillholes. Dahrouge completed a data compilation and review of the geological logs and drilling location map to evaluate their consistency to what was observed in the field during the mapping campaign. The drillhole map was then georeferenced based on available data, such as topography and state plain section corner, to determine relative historical drillhole locations (Figure 1). The historical drillholes have been overlain on the preliminary geological model to evaluate consistency of the historical logs to the detailed mapping completed during Q1 2024.

 

During the data compilation, Dahrouge also evaluated how the historical analytical results compared to surface grab and paleochannel mineralization. As previously highlighted in (March 25, 2024, press release), the field samples from the area of historical drilling returned values of 3.55% U3O8 and 5.34% V2O5. The historical data in conjunction with geological and analytical data collected by Dahrouge, does provide direct insight into potential mineralization on the Property. The results outlined in Table 1, do provide guidance to interpreted mineralized paleochannel and will be used to help guide future drilling campaigns.

 

Table 1: Historical Drillhole Information

In reviewing the historical drillhole data and geologic interpretations, Dahrouge surmised that the historic drill program was following a trend that was interpreted as paleochannel hosting mineralization. This trend matches the structural measurements and mineralization trend hypothesis from Dahrouge's recent mapping program, helping us to target possible mineral-hosting paleochannels extending throughout the Property (Figure 1). This historic data provides key geological information and when combined with data collected from surface mapping and sampling, guides the generation of the preliminary geological model and drillhole targeting.

 

Figure 1: Map of interpreted paleochannel that historical drilling targeted

 

Figure 2: ESRS-007 sample outcrop.

 

Figure 3: An annotated picture depicting the sedimentary structures that make up the mineralized paleochannels on the Energy Sands Project.

NI 43-101 Disclosure

The technical content of this news release has been reviewed and approved by Jacob Anderson, CPG, MAusIMM, who is a Resource Geologist for Dahrouge Geological Consulting USA Ltd., and a Qualified Person under National Instrument 43-101, who has prepared and/or reviewed the content of this press release.

 

The results discussed in this document are historical. Pegasus nor the qualified person have performed sufficient work or data verification of the historical data. Although the historical results may not be reliable, the Company nevertheless believes that they provide an indication of the Property's potential and are relevant for any future exploration program.

 

References

Doelling, H.H., Kuehne, P.A., Willis, G.C., Ehler, J.B., 2015, Geologic map of the San Rafael desert 30' x 60' quadrangle, Emery and Grand counties, Utah, Utah Department of Natural Resources.

 

About Pegasus Resources Inc.

Pegasus Resources Inc. is a diversified Junior Canadian Mineral Exploration Company with a focus on uranium, gold, and base metal properties in North America. The Company is also actively pursuing the right opportunity in other resources to enhance shareholder value. For additional information, please visit the Company at www.pegasusresourcesinc.com.

 

On Behalf of the Board of Directors:

Christian Timmins
President, CEO and Director

Pegasus Resources Inc.
700 - 838 West Hastings Street
Vancouver, BC V6C 0A6
PH: 1-403-597-3410

X: https://twitter.com/MrChris_Timmins
X: https://twitter.com/pegasusresinc
E: info@pegasusresourcesinc.com

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

 

Forward-Looking Statements
Statements included in this announcement, including statements concerning the Company's plans, intentions, and expectations, which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements." Forward-looking statements may be identified by words including "anticipates," "believes," "intends," "estimates," "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.

 

SOURCE: Pegasus Resources Inc.

 

Pegasus Resources Inc. (TSX-V:PEGA) (OTCPK:SLTFF) (Frankfurt:0QS0) is a featured mining stock on Investorideas.com

 

More info on PEGA at Investorideas.com Visit: https://www.investorideas.com/CO/PEGA/

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact management and IR of each company directly regarding specific questions. Disclosure: Pegasus Resources Inc is a paid for mining client at InvestorIdeas.com. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

 

Get more mining stock investor ideas- news, articles, and podcasts and stock directories

 

 

Breaking Gold Stock News: Great Atlantic (TSXV: $GR.V) Initiates Spending On Fully Funded Planned Bulk Sample $4,000,000 Estimated to be spent in ground at Jaclyn Main Zone Starting with Guidance Imaging Diamond Drilling Program; @GreatATLres

100% Owned Golden Promise Gold Property Newfoundland

FOCUSED ON EXPLORING ATLANTIC CANADA

 

VANCOUVER, British Columbia - June 4, 2024 (Investorideas.com Newswire) GREAT ATLANTIC RESOURCES CORP. (TSXV:GR; FRA: PH02) (the "Company" or "Great Atlantic") is pleased to announce it has applied for a diamond drilling permit through its wholly owned subsidiary, Golden Promise Mines Inc., for its Golden Promise Gold Property, located in central Newfoundland. The application is for nine drill holes at the Jaclyn Main Zone which hosts gold bearing quartz veins, including high grade gold mineralization. These guidance imaging holes are targeting the area of our fully funded planned bulk sample.

This news is paid advertisement/ news disseminated on behalf of/issued on behalf of Great Atlantic Resources

Read this news, featuring GR.V in full at https://www.investorideas.com/news/2024/06041GR-Diamond-Drilling-Program.asp

 

The opportunity to complete a fully funded bulk sample at the Jaclyn Main Zone using non-dilutive capital is a major milestone for the company. I would strongly encourage investors to look at the consortium working with Great Atlantic to complete this task. Taking a hands-on approach, I have traveled to the Netherlands to meet with the innovative Dutch Drilling team. After reviewing their previous engineering feats, the modifications made to the Bore Drill process that will be utilized for this project have only solidified my confidence in our potential success. This confidence extends not only to completing a bulk sample but also to advancing the balance of our current resource and the known and unknown high-grade gold veins within the complex of our property, which is located next to CXB.v, a soon to be proven producer within the Exploits Subzone" States Anderson CEO Great Atlantic.

The objective of the guidance imaging diamond drilling is to further define gold bearing quartz veins in one specific area of the Company's resource where the bulk sample is planned with its partner Novamera Inc. Extraction of the bulk sample will utilize a precision mining method powered by Novamera's proprietary Surgical Mining technologies (Novamera Website). The partners are currently finalizing the bulk sample program application and anticipating final approval by end of summer. Once permitting is approved, which is expected in the next few months, execution will be implemented. The program is fully funded with an anticipated spend in the ground of $4,000,000.00, which is being provided through the consortium with Digital. https://www.digitalsupercluster.ca/projects/data-driven-surgical-mining.

These guidance imaging drill holes will be initiated within the west region of the Jaclyn Main Zone targeting gold bearing veins to approximately 100 meters vertical depth.

 Great Atlantic confirmed high-grade gold in quartz veins in the west region of the Jaclyn Main Zone during 2019 and 2021 diamond drilling programs, including near surface intercepts (core length) of 113.07 grams / tonne (g/t) gold over 0.55 meters and 61.35 g/t gold over 2.04 meters that are located within the area of the Company's current resource (see Company news releases for results of 2019 and 2021 diamond drilling program).

The planned bulk sample at the Jaclyn Main Zone will be approximately 2,700 tonnes, to be extracted using a precision mining method, powered by Novamera's proprietary Surgical Mining technologies. The program at the Jaclyn Main Zone is being funded in part by co-investment from DIGITAL, Canada's Global Innovation Cluster for digital technologies, as part of a larger project that aims to support data-driven and digital solutions within the mining sector. The Link to the announcement can be found at https://www.digitalsupercluster.ca/projects/data-driven-surgical-mining.

Great Atlantic reported a National Instrument 43-101 compliant inferred resource estimate during late 2018 for the Jaclyn Main Zone of 357,500 tonnes at 10.4 g/t gold (119,900 ounces of gold - uncapped) (Company News Release of December 6, 2018; and Sedar-filed National

Instrument 43-101 Technical Report on the Golden Promise Property, Central Newfoundland (revised), dated December 4, 2018 by Mr. Greg Z. Mosher, M.Sc. App., P.Geo., and Mr. Larry Pilgrim, B.Sc., P.Geo.). The reported inferred mineral resource estimate for the Jaclyn Main Zone is as follows:

Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability.

There is no certainty that all or any part of the Mineral Resources estimated will be converted into Mineral Reserves.

Mineral resource tonnage and contained metal have been rounded to reflect the accuracy of the estimate, and numbers may not add due to rounding.

Mineral resource tonnage and grades are reported as undiluted.

Contained Au ounces are in-situ and do not include recovery losses

The Golden Promise Gold Property is the largest and most advanced of eight central Newfoundland gold properties owned by Golden Promise Mines Inc. and located within the Exploits Subzone of the Newfoundland Dunnage Zone. One of these properties (Golden Trust) is located within one kilometer of the Valentine Gold Mine of Calibre Mining Corp. (TSX: CXB; OTCQX: CXBMF) which is also located within the Exploits Subzone. Readers are warned that mineralization at the Valentine Gold Mine is not necessarily indicative of mineralization at the Golden Promise Property or any of the other central Newfoundland gold properties of Golden Promise Mines Inc.

David Martin, P.Geo., (New Brunswick and Newfoundland and Labrador), a Qualified Person as defined by NI 43-101 and VP Exploration for Great Atlantic, is responsible for the technical information contained in this News Release.

On Behalf of the board of directors

"Christopher R Anderson"

Mr. Christopher R. Anderson

President CEO Director

604-488-3900 - Office

Investor Relations: 1-416-628-1560 IR @ GreatAtlanticResources.com

About Great Atlantic Resources Corp.:

Great Atlantic Resources Corp. is a Canadian exploration company focused on the discovery and development of mineral assets in the resource-rich and sovereign risk-free realm of Atlantic Canada, one of the number one mining regions of the world. Great Atlantic is currently surging forward building the company utilizing a Project Generation model, with a special focus on the most critical elements on the planet that are prominent in Atlantic Canada, Gold, Copper, Zinc, Nickel, Cobalt, Antimony and Tungsten.

This press release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address future exploration drilling, exploration activities and events or developments that the Company expects, are forward looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include exploitation and exploration successes, continued availability of financing, and general economic, market or business conditions.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Great Atlantic Resource Corp.

888 Dunsmuir Street - Suite 888, Vancouver, B.C., V6C 3K4

Great Atlantic Resource Corp. (TSXV: GR) is a featured mining stock on Investorideas.com

More info on GR at Investorideas.com Visit: https://www.investorideas.com/CO/GR/

Disclaimer/Disclosure: GREAT ATLANTIC RESOURCES CORP. (TSXV.GR) is a paid featured mining stock on Investor Ideas. More info:Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact management and IR of each company directly regarding specific questions. More disclaimer and disclosure info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

 

Get more mining stock investor ideas- news, articles, and podcasts and stock directories

 

Blood Purification Medical Devices Stocks in the News (NASDAQ: $AEMD) (NASDAQ: $CTSO) (NASDAQ: $CERS) (NYSE: $BAX) (TSX: $EDT.TO) @CytoSorbents @SpectralMedical @baxter_intl

 

Blood Purification Medical Devices Stocks in the News (NASDAQ: $AEMD) (NASDAQ: $CTSO) (NASDAQ: $CERS) (NYSE: $BAX) (TSX: $EDT.TO) @CytoSorbents @SpectralMedical @baxter_intl

 

Revolutionizing the Future of Health from Cancer to COVID

 

June 3, 2024 - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at medical device advancements for blood purification, featuring Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

 

According to Straits Research ”The global blood purification equipment market size was valued at USD 17,755.6 million in 2021. It is expected to reach USD 29242.21 million by 2030.”

 

Aethlon Medical, Inc. (Nasdaq: AEMD), with a long history of development for its patented Hemopurifier® blood purification device, just released an update on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.

 

This news is paid advertisement/ news disseminated on behalf of/issued on behalf of Aethlon Medical

 

Read this article, featuring AEMD in full at https://www.investorideas.com/news/2024/biotech/06031Blood-Purification-Medical-Devices.asp

 

"We continue to make progress preparing for our planned, safety, feasibility and “dose finding” oncology trials in Australia and India, and want to provide our shareholders and other constituents with an update”, stated Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical. “In early May, we announced new data showing the in vitro removal of exosomes from cancer patient plasma using a miniature version of our Hemopurifier®. This data has been quickly integrated into the required documentation for Ethics Committees at our potential clinical sites. On May 17, 2024, we provided these documents to the Contract Research Organizations for these planned clinical trials. Subsequently, on May 24, 2024, one potential site submitted the documents to its Ethics Board.  An additional site in Australia and another in India are currently assembling the packages for submission to their Ethics Committees.”

 

“Once we receive the expected Ethics Committee approvals, we will finalize the Clinical Trial Agreements. After this, hospitals can begin recruiting patients for the trials.”

 

As a reminder, the target patient population for these safety, feasibility, and dose finding trials is oncology patients with solid tumors who are failing their anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.

 

The Aethlon Hemopurifier® is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and circulating viruses. The United States Food and Drug Administration (FDA) has designated the Hemopurifier® as a “Breakthrough Device” for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and life-threatening viruses that are not addressed with approved therapies.

 

Zach’s Research recently commented on Aethlon following positive data from an in vitro binding study it had implemented of the potential for the Hemopurifier® to remove extracellular vesicles (EVs) directly from plasma of cancer patients.

 

“The data from this in vitro study is a critical element enabling the company to move the Hemopurifier forward in clinical oncology studies towards potential regulatory approval and commercialization. The company next intends to add this data to its Clinical Investigator Brochure, which will then be submitted to the Ethics Committees at clinical sites that are interested in participating in the planned phase 1 oncology trials in Australia and India. We expect AEMD to submit the Clinical Investigator Brochure this month.”

 

“AEMD will then seek to obtain approval by the respective Ethics Boards of interested sites in India. The company has a strong clinical working relationship with Medanta Medicity Hospital in Delhi, India, which is currently participating in a study of the Hemopurifier in COVID patients and it would not surprise us if Medanta Medicity Hospital had interest in participating in the oncology study.”

 

“Depending on how long it takes for the sites to review and potentially approve moving forward to participate in Aethlon’s phase 1 trial, we believe clinical efforts could begin in 2H24. If Aethlon can demonstrate the ability of the Hemopurifier to improve outcomes of cancer patients suffering from a variety of different cancer types, we would anticipate strong commercial prospects for the Hemopurifier.”

 

In early May, CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, announced unaudited financial and operating results for the quarter ended March 31, 2024. The Company reported a robust 14% increase in product sales year over year and a sequential quarterly increase of 22%.

 

Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, “We are pleased to announce a strong start to 2024, driven by significant sales growth and operational efficiencies. First quarter 2024 product sales were $9.0 million, marking the highest quarter for core CytoSorb sales in nearly 3 years. We expanded our product gross margins to 76%, exclusive of a non-recurring inventory adjustment, up an absolute 8% from Q1 2023, which we believe highlights the scalability and efficiency of our state-of-the-art manufacturing facility and processes.”

 

Furthermore, Principal Investigator Dr. Michael Mack presented the results of the U.S. and Canada pivotal STAR-T (Safe and Timely Antithrombotic Removal of Ticagrelor) randomized controlled trial at the Annual Meeting of the American Association for Thoracic Surgery (AATS) and at the KOL and Investor/Analyst Day we hosted earlier this week (replay available) that we believe support a favorable benefit-to-risk profile of the DrugSorb-ATR system* in the perioperative bleeding risk of patients undergoing isolated coronary artery bypass graft (CABG) surgery within 2 days of receiving Brilinta® (ticagrelor, AstraZeneca). We received positive and encouraging feedback on the importance of these data and the continued unmet medical need from cardiothoracic surgeons. Looking ahead, we expect to submit marketing applications for DrugSorb-ATR, which has an FDA Breakthrough Device Designation, to the FDA under the De Novo pathway, and Health Canada in the third quarter of 2024.”

 

Also focused on blood purification, Cerus Corporation (Nasdaq: CERS), dedicated solely to safeguarding the world’s blood supply, announced financial results for the first quarter ended March 31, 2024.

 

Highlights included:

 

·        U.S. ReCePI Phase 3 clinical trial successfully met primary endpoint for INTERCEPT Blood System for Red Blood Cells in cardiovascular surgery patients.

 

·        Received FDA approval of extended shelf life for INTERCEPT Platelet Processing Sets to 12 months, doubling the previous shelf life.

 

·        Advanced the LED illuminator program towards the Company’s target commercial launch in the EU in 2025.

 

The Company is reiterating its full-year 2024 annual product revenue guidance range of $172 million to $175 million. Included in this range is full-year 2024 guidance for INTERCEPT Fibrinogen Complex, which is expected to be between $8 million to $10 million.

 

"The Cerus team delivered against our plans for Q1, paving the way for the balance of 2024, with great progress on clinical milestones and a strong return to growth for our commercial business. The positive topline readout from ReCePI, the U.S. Phase 3 clinical trial for INTERCEPT Red Blood Cells, is a significant milestone for the program and for our efforts to potentially bring this product to the market globally," stated William "Obi" Greenman, Cerus’ President and Chief executive Officer. "Red blood cells are the most commonly transfused blood components worldwide, and we are committed to providing the full INTERCEPT portfolio for all transfused blood components to our customers around the globe."

 

The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System of Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding associated with fibrinogen deficiency, including massive hemorrhage.

 

In mid- May, Spectral Medical Inc. (TSX: EDT), a Phase 3 company seeking US FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”), announced its financial results for the first quarter ended March 31, 2024, and provided a corporate update. 

 

PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.

 

Spectral has continued its significant progress throughout the first quarter of 2024 both clinically and operationally and year-to-date enrolled 25 patients for a total of 106 patients out of the 150 total patient’s target. The Company is focused on the final push to fully enroll and finish the Tigris trial and believes that the continued onboarding of new Tigris sites since the fourth quarter of 2023 could further accelerate enrollment and allow Spectral to rapidly reach the 150-patients target, bringing the Company closer to FDA submission and potential FDA approval. In parallel to its clinical trial, the Company continues to work closely with its commercialization partner, Baxter. In Q1 2024, Baxter exercised its right to maintain its exclusive distribution for PMX products in the U.S. and Canada and paid Spectral a non-dilutive milestone payment. Additionally, Spectral and Baxter mutually agreed to amend the initial term of their commercial partnership to ten years post-FDA approval of PMX. The Company believes this amendment provides a mutually beneficial runway for the parties to maximize PMX commercial economics, while providing motivation for continued support and allocation of resources to the PMX partnership.

 

Blood Purification technology made headlines during the pandemic when several companies including Baxter International Inc. (NYSE:BAX) received emergency use authorization (EUA) from the US FDA. Baxter’s approval was for the company's Oxiris filter set to treat patients who have confirmed COVID-19 and have been admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure in need of blood purification therapy to reduce pro-inflammatory cytokine levels, including use in continuous renal replacement therapy (CRRT). 

 

Separate from its current focus on cancer treatment, Aethlon (Nasdaq: AEMD) investigates the potential for the use of the Hemopurifier® in viral diseases under an open Investigational Device Exemption (IDE) and their FDA Breakthrough Designation for “…the treatment of life-threatening glycosylated viruses that are not addressed with an approved therapy.” 

 

Based on our studies to date, the Hemopurifier can potentially clear many viruses that are pathogenic in humans, including HCV, HIV, Sars-CoV-2, and Ebola.”

 

For the companies in this sector, the drive for innovation is ‘in their blood‘, and with the global threats of viruses and future pandemics on the rise, it’s a sector worth watching.

 

Research biotech and medical device/ tech stocks at Investorideas.com

https://www.investorideas.com/BIS/Stock_List.asp

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: This news article featuring AEMD is a paid for news release on Investorideas.com -Our site does not make recommendations for purchases or sale of stocks, services or products.  This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800-665-0411

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

 

Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies

 

Breaking Medical Technology News: Aethlon Medical (NASDAQ: $AEMD) Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies

 

Phase 1 Clinical Trials of the Hemopurifier® Designed to Include Patients With Solid Tumors Who Have Stable or Progressive Disease During Anti-PD-1 Monotherapy Treatment, Such as Keytruda® of Opdivo®

 

Interested Clinical Sites Have Initiated Submissions For Ethics Committee Review

 

SAN DIEGO, CA - June 3, 2024 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided the following update on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.

 

This news is paid advertisement/ news disseminated on behalf of/issued on behalf of Aethlon Medical Inc.

 

Read this news, featuring AEMD in full at https://www.investorideas.com/news/2024/06031AEMD-Phase-1-Cancer-Treatment-Studies.asp

"We continue to make progress preparing for our planned, safety, feasibility and "dose finding" oncology trials in Australia and India, and want to provide our shareholders and other constituents with an update, stated Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical. In early May, we announced new data showing the in vitro removal of exosomes from cancer patient plasma using a miniature version of our Hemopurifier®. This data has been quickly integrated into the required documentation for Ethics Committees at our potential clinical sites. On May 17, 2024, we provided these documents to the Contract Research Organizations for these planned clinical trials. Subsequently, on May 24, 2024, one potential site submitted the documents to its Ethics Board. An additional site in Australia and another in India are currently assembling the packages for submission to their Ethics Committees.

 

Once we receive the expected Ethics Committee approvals, we will finalize the Clinical Trial Agreements. After this, hospitals can begin recruiting patients for the trials.

As a reminder, the target patient population for these safety, feasibility, and dose finding trials is oncology patients with solid tumors who are failing their anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.

 

About Aethlon and the Hemopurifier®

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Additional information can be found at www.AethlonMedical.com.

 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to successfully raise additional capital and to complete development of the Hemopurifier and to successfully demonstrate the utility of the Hemopurifier in cancer and infectious diseases; the Company's ability to demonstrate synergies of the Hemopurifier with the NucleoCapture and HemoNucleoCapture devices; the Company's ability to enter into a future collaboration with Santersus; the Company's ability to complete the internal binding study of relevant extracellular vesicles; the Company's ability to commence and manage its clinical trials; and other potential risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2023, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

 

Company Contact:
Jim Frakes
Interim Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com

 

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com

917-513-5303

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

 

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

 

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: Aethlon Medical, Inc. (NASDAQ:AEMD) is a paid featured stock on Investorideas.com More disclaimer info:  https://www.investorideas.com/About/News/Clientspecifics.asp  https://www.investorideas.com/About/Disclaimer.asp

Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks